Are dermatomyositis and polymyalgia rheumatica the same condition?

No, dermatomyositis and polymyalgia rheumatica are distinct diseases that must be differentiated

Dermatomyositis and polymyalgia rheumatica are separate conditions with fundamentally different pathophysiology, clinical presentations, and treatment implications—confusing them can lead to serious diagnostic errors and inappropriate management.

Key Distinguishing Features

Dermatomyositis

Dermatomyositis is an inflammatory myopathy characterized by:

• True muscle weakness (not just pain)—patients have difficulty standing from a seated position, lifting arms, and climbing stairs 1
• Characteristic skin manifestations: heliotrope rash, Gottron papules, periorbital edema, photosensitive erythematous rash 2
• Elevated muscle enzymes: markedly elevated creatine kinase (CK), often >10 times normal 3
• Muscle inflammation on testing: EMG shows myopathic changes with fibrillations; MRI demonstrates muscle edema and inflammation 3
• Potential for severe complications: can involve myocardium, cause rhabdomyolysis, and has association with malignancy 1, 4

Polymyalgia Rheumatica

Polymyalgia rheumatica presents with:

• Pain without true weakness—patients experience severe myalgia and stiffness but maintain normal strength 1, 3
• No skin manifestations (unless coincidental drug eruption) 5
• Normal or minimally elevated CK—muscle enzymes remain within normal limits, differentiating it from myositis 1, 3
• No evidence of muscle inflammation: MRI and EMG should not show myopathy or muscle inflammation 1, 3
• Highly elevated inflammatory markers: ESR and CRP are markedly elevated 1
• Affects older adults: typically >50 years, most common >70 years 4, 6

Critical Diagnostic Algorithm

When evaluating proximal muscle symptoms:

1. Assess for true weakness vs. pain

   • Can the patient generate normal strength against resistance despite pain? → Consider PMR
   • Does the patient have objective weakness with difficulty performing tasks? → Consider dermatomyositis

2. Check CK levels immediately

   • Normal CK → PMR likely
   • Elevated CK (especially >3x normal) → dermatomyositis or other myositis 1, 3

3. Examine skin carefully

   • Characteristic rash present → dermatomyositis
   • No rash → PMR more likely (though amyopathic dermatomyositis exists)

4. Evaluate inflammatory markers

   • Both conditions show elevated ESR/CRP, so this alone cannot differentiate 1

5. Consider imaging if diagnosis uncertain

   • MRI showing muscle edema/inflammation → myositis
   • MRI without muscle inflammation (may show mild shoulder effusion) → PMR 1

Common Diagnostic Pitfall

The most dangerous error is misdiagnosing dermatomyositis as PMR 7. This occurs because:

• Both affect older adults with proximal symptoms
• Both have elevated inflammatory markers
• Patients with dermatomyositis may initially complain more of pain than weakness
• Rare cases of PMR with drug eruptions can mimic dermatomyositis skin changes 5

Always check CK levels and assess for true weakness before diagnosing PMR. If CK is elevated or true weakness exists, pursue workup for inflammatory myopathy with EMG, MRI, and potentially muscle biopsy 3.

Treatment Implications

The distinction matters critically for treatment:

• PMR: Responds dramatically to moderate-dose glucocorticoids (prednisone 12.5-25 mg/day) 4
• Dermatomyositis: Requires high-dose glucocorticoids (prednisone 60 mg/day or 1 mg/kg) plus steroid-sparing agents (methotrexate, azathioprine, mycophenolate) from onset 2, 3
• Severe dermatomyositis: May require IV methylprednisolone, IVIG, cyclophosphamide, or rituximab 2

Dermatomyositis can be life-threatening with cardiac involvement and has malignancy associations requiring cancer screening 1, 4. PMR, while causing significant morbidity, does not carry these severe risks but requires monitoring for giant cell arteritis 4, 6.